Comparative functional analysis between human and mouse chitotriosidase: Substitution at amino acid 218 modulates the chitinolytic and transglycosylation activity.


Journal

International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578

Informations de publication

Date de publication:
01 Dec 2020
Historique:
received: 07 05 2020
revised: 11 08 2020
accepted: 21 08 2020
pubmed: 28 8 2020
medline: 17 4 2021
entrez: 28 8 2020
Statut: ppublish

Résumé

Chitotriosidase (Chit1) and acidic mammalian chitinase (AMCase) have been attracting research interest due to their involvement in various pathological conditions such as Gaucher's disease and asthma, respectively. Both enzymes are highly expressed in mice, while the level of AMCase mRNA was low in human tissues. In addition, the chitinolytic activity of the recombinant human AMCase was significantly lower than that of the mouse counterpart. Here, we revealed a substantially higher chitinolytic and transglycosylation activity of human Chit1 against artificial and natural chitin substrates as compared to the mouse enzyme. We found that the substitution of leucine (L) by tryptophan (W) at position 218 markedly reduced both activities in human Chit1. Conversely, the L218W substitution in mouse Chit1 increased the activity of the enzyme. These results suggest that Chit1 may compensate for the low of AMCase activity in humans, while in mice, highly active AMCase may supplements low Chit1 activity.

Identifiants

pubmed: 32853624
pii: S0141-8130(20)34265-3
doi: 10.1016/j.ijbiomac.2020.08.173
pii:
doi:

Substances chimiques

Recombinant Proteins 0
Chitin 1398-61-4
Hexosaminidases EC 3.2.1.-
chitotriosidase EC 3.2.1.-
Chitinases EC 3.2.1.14

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2895-2902

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest All authors have no competing interests to declare.

Auteurs

Masahiro Kimura (M)

Department of Chemistry and Life Science, Kogakuin University, Hachioji, Tokyo 192-0015, Japan; Research Fellow of Japan Society for the Promotion of Science (PD), Koujimachi, Chiyoda-ku, Tokyo 102-0083, Japan; Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan.

Takashi Watanabe (T)

Department of Chemistry and Life Science, Kogakuin University, Hachioji, Tokyo 192-0015, Japan.

Kazutaka Sekine (K)

Department of Chemistry and Life Science, Kogakuin University, Hachioji, Tokyo 192-0015, Japan.

Hitomi Ishizuka (H)

Department of Chemistry and Life Science, Kogakuin University, Hachioji, Tokyo 192-0015, Japan.

Aoi Ikejiri (A)

Department of Chemistry and Life Science, Kogakuin University, Hachioji, Tokyo 192-0015, Japan.

Masayoshi Sakaguchi (M)

Department of Chemistry and Life Science, Kogakuin University, Hachioji, Tokyo 192-0015, Japan.

Minori Kamaya (M)

Department of Applied Chemistry, Kogakuin University, Hachioji, Tokyo 192-0015, Japan.

Daisuke Yamanaka (D)

Laboratory for Immunopharmacology of Microbial Products, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan.

Vaclav Matoska (V)

Laboratory of Molecular Diagnostics, Department of Clinical Biochemistry, Hematology and Immunology, Homolka Hospital, Roentgenova 37/2, Prague 150 00, Czech Republic.

Peter O Bauer (PO)

Laboratory of Molecular Diagnostics, Department of Clinical Biochemistry, Hematology and Immunology, Homolka Hospital, Roentgenova 37/2, Prague 150 00, Czech Republic; Bioinova Ltd., Videnska 1083, Prague 142 20, Czech Republic.

Fumitaka Oyama (F)

Department of Chemistry and Life Science, Kogakuin University, Hachioji, Tokyo 192-0015, Japan. Electronic address: f-oyama@cc.kogakuin.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH